OSR (NASDAQ:OSRH – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare OSR to similar businesses based on the strength of its valuation, dividends, analyst recommendations, profitability, earnings, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current recommendations for OSR and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 9873 | 15287 | 45630 | 1598 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 125.20%. Given OSR’s competitors stronger consensus rating and higher probable upside, analysts clearly believe OSR has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares OSR and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | $1.81 million | -$27.06 million | -0.27 |
| OSR Competitors | $702.30 million | $9.48 million | -18.96 |
OSR’s competitors have higher revenue and earnings than OSR. OSR is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
55.3% of OSR shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares OSR and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | -593.15% | -8.36% | -6.24% |
| OSR Competitors | -12,323.33% | -195.91% | -30.60% |
Risk and Volatility
OSR has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, OSR’s competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Summary
OSR beats its competitors on 7 of the 13 factors compared.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
